ClinicalTrials.gg
Not yet recruitingNCT07945860Updated Nov 18, 2026

Conduction System Pacing Versus Conventional Right Ventricular Pacing in Adults With Atrioventricular Block

An interventional study of Conduction System Pacing and Conventional Right Ventricular Pacing in Atrioventricular Block, sponsored by Sheba Medical Center. Not yet recruiting at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Sheba Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study compares two ways of pacing the heart in adults with atrioventricular block, a condition in which electrical signals do not pass normally from the upper to the lower heart chambers. Participants must need a permanent pacemaker and have a left ventricular ejection fraction of at least 50% before implantation. Ejection fraction measures how much blood the main pumping chamber ejects with each beat.

The study will include 150 participants at Sheba Medical Center. By chance, 50 participants will receive conduction system pacing, which aims to stimulate the heart through its natural electrical conduction system, and 100 will receive conventional right ventricular pacing. Participants and treating clinicians will know which treatment is used.

The main question is whether the two pacing strategies differ in heart pumping function 24 months after implantation, taking the starting measurement into account. Researchers will also compare quality of life, heart-related emergency visits and hospitalizations, complications, pacemaker and lead function, repeat procedures, and use of healthcare resources.

Heart pumping function will be measured before implantation and at 12 and 24 months. Participants will complete the AQUAREL quality-of-life questionnaire before implantation and at 12, 24, 36, 48, and 60 months. Device follow-up will include routine clinical care and remote monitoring.

Read the detailed description

Outcomes Over Devices is a prospective, randomized, open-label, two-arm, single-center study comparing conduction system pacing (CSP) with conventional right ventricular pacing (RVP). The clinical indication for permanent pacing is established before recruitment. Randomization is 1:2 (50 CSP; 100 RVP), using a concealed computer-generated sequence with variable block sizes, stratified by baseline left ventricular ejection fraction (LVEF) of 50-59% versus at least 60%, without fixed quotas per stratum.

The primary analysis follows the intention-to-treat principle. The primary estimand is the between-arm difference in LVEF at 24 months, adjusted for baseline LVEF and stratification factors as appropriate. Post-baseline measurements at 12 and 24 months will be analyzed using a repeated-measures model with treatment arm, time, and their interaction. The 12-month evaluation is exploratory. The three AQUAREL domains will be scored and analyzed separately, with baseline adjustment and multiplicity addressed for the secondary 24-month comparisons. Detailed modeling and sensitivity analyses will be prespecified in the statistical analysis plan before unblinded comparative analyses.

Failure to achieve the allocated pacing strategy will not itself exclude a participant. Alternative pacing may be used when clinically necessary, with reasons and actual treatment documented; original allocation remains the basis for intention-to-treat analysis where possible. Actual ventricular pacing burden will be recorded and evaluated in prespecified secondary analyses. An independent Clinical Events Adjudication Committee will review prespecified clinical and device-related events, with arm masking where feasible.

The study is initiated by Sheba Medical Center. Medtronic does not fund the study; CSP systems are purchased under a discounted commercial arrangement. A separate, potentially outcome-based commercial reconciliation after 12 months does not determine clinical treatment or alter randomization, follow-up, data collection, analysis, or publication independence.

02

Conditions studied

  • Atrioventricular Block
03

In context

Atrioventricular Block

118 studies on the registry are indexed under Atrioventricular Block; 44 are open to participants now.

This study's planned enrollment of 150 is above the median of 130 across 79 interventional studies indexed under Atrioventricular Block.

Browse Atrioventricular Block studies →

Lead sponsor

Sheba Medical Center is the lead sponsor of 680 studies on the registry; 65 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Clinical indication for permanent pacemaker implantation due to atrioventricular block.
  • Pre-implantation echocardiographic of at least 50%.
  • Ability to understand the study and sign .

Exclusion criteria

Exclusion Criteria:

  • Unable to provide .
  • Estimated of less than 12 months.
  • Severe medical condition likely to prevent completion of follow-up.
  • Existing indication for cardiac resynchronization therapy at recruitment.
  • Required pacing system or treatment incompatible with either study arm.
  • Concurrent interventional study likely to materially affect study outcomes.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Conduction System Pacing

    50 participants allocated to conduction system pacing using a Medtronic SelectSecure MRI SureScan Model 3830 lead placed at the His bundle or left bundle branch area. Final lead position and programming are determined by the implanting electrophysiologist according to anatomy, electrical measurements, and clinical judgment.

    Device: Conduction System Pacing

  • Active comparator
    Conventional Right Ventricular Pacing

    100 participants allocated to conventional right ventricular pacing using a standard pacing lead and conventional right ventricular lead position, according to usual clinical practice at the study center. Other medical treatment and device programming are determined by clinical need.

    Device: Conventional Right Ventricular Pacing

Interventions

  • DeviceConduction System Pacing

    Permanent pacing using a Medtronic SelectSecure MRI SureScan Model 3830 lead targeting His-bundle or left bundle branch area pacing. Final lead placement, fixation, and programming follow electrophysiological measurements and clinical judgment. Where feasible, the same pacemaker generator platform is used in both study arms.

  • DeviceConventional Right Ventricular Pacing

    Permanent pacemaker implantation with a conventional right ventricular pacing lead placed at a standard right ventricular site according to usual clinical practice at Sheba Medical Center. Device programming and accompanying medical treatment are determined by clinical need.

06

What researchers measure

Primary outcomes

  1. Left Ventricular Ejection Fraction at 24 Months

    Left ventricular ejection fraction (LVEF), expressed as a percentage and measured by echocardiography at 24 months after implantation. The primary comparison is the between-arm difference adjusted for baseline LVEF and stratification factors as appropriate. The primary analysis follows the intention-to-treat principle.

    Time frame: 24 months after pacemaker implantation.

Secondary outcomes

  1. Change From Baseline in AQUAREL Chest Discomfort Domain Score

    Change from baseline in the AQUAREL chest discomfort domain, scored separately using the original algorithm. Domain scores range from 0 to 100; higher scores indicate better quality of life and positive changes indicate improvement. The secondary between-arm comparison at 24 months is adjusted for baseline domain score, with multiplicity addressed across the three domains. The 12-month analysis is exploratory; longer-term scores are also collected.

    Time frame: Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.

  2. Change From Baseline in AQUAREL Arrhythmia Domain Score

    Change from baseline in the AQUAREL arrhythmia domain, scored separately using the original algorithm. Domain scores range from 0 to 100; higher scores indicate better quality of life and positive changes indicate improvement. The secondary between-arm comparison at 24 months is adjusted for baseline domain score, with multiplicity addressed across the three domains. The 12-month analysis is exploratory; longer-term scores are also collected.

    Time frame: Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.

  3. Change From Baseline in AQUAREL Exertional Dyspnea Domain Score

    Change from baseline in the AQUAREL exertional dyspnea domain, scored separately using the original algorithm. Domain scores range from 0 to 100; higher scores indicate better quality of life and positive changes indicate improvement. The secondary between-arm comparison at 24 months is adjusted for baseline domain score, with multiplicity addressed across the three domains. The 12-month analysis is exploratory; longer-term scores are also collected.

    Time frame: Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.

  4. Ventricular Pacing Burden

    Percentage of ventricular beats paced, obtained from device interrogation. Actual pacing burden is an explanatory secondary variable and is not a randomization criterion.

    Time frame: Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.

  5. Ventricular Pacing Capture Threshold

    Ventricular capture threshold, expressed in volts, measured during device interrogation. Measurements are recorded with the corresponding device settings to assess pacing performance over follow-up.

    Time frame: Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.

  6. Ventricular Sensing Amplitude

    Amplitude of sensed ventricular signals, expressed in millivolts, measured during device interrogation to assess lead and device performance over follow-up.

    Time frame: Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.

  7. Cardiac or Pacing/Procedure-Related Emergency Department Visits

    Number of emergency department visits related to cardiac disease, pacing, or the implantation procedure. Relevant events will be reviewed by the Clinical Events Adjudication Committee under definitions established before enrollment.

    Time frame: From pacemaker implantation through 24 months after implantation (cumulative event count).

  8. Cardiac or Pacing/Procedure-Related Hospitalizations

    Number of hospital admissions related to cardiac disease, pacing, or the implantation procedure. Relevant events will be reviewed by the Clinical Events Adjudication Committee under definitions established before enrollment.

    Time frame: From pacemaker implantation through 24 months after implantation (cumulative event count).

  9. Heart Failure Events

    Number of heart failure events during follow-up, reviewed by the Clinical Events Adjudication Committee. Written event definitions and adjudication procedures will be established before enrollment as specified in the protocol.

    Time frame: From pacemaker implantation through 24 months after implantation (cumulative event count).

  10. Additional Cardiac Interventions

    Number of additional cardiac interventions during follow-up. The indication, date, effects on LVEF or the pacing system, lead changes, and subsequent management will be recorded. Medically necessary interventions are permitted in either study arm.

    Time frame: From pacemaker implantation through 24 months after implantation (cumulative event count).

  11. Device-, Lead-, and Procedure-Related Complications

    Number of device-, lead-, and procedure-related complications. Events include implantation complications and lead or device problems such as infection, bleeding, pneumothorax, perforation or tamponade, lead dislodgement or fracture, insulation failure, and failure to capture or sense. Major events and relatedness will be reviewed by the Clinical Events Adjudication Committee.

    Time frame: From pacemaker implantation through 24 months after implantation (cumulative event count).

  12. Repeat Pacing Procedures, Lead Revisions or Replacements, and System Upgrades

    Number of repeat procedures involving the pacing system, including lead revision or replacement and system upgrade. Procedure type, indication, date, and resulting changes to the pacing system will be documented. Events will be reviewed by the Clinical Events Adjudication Committee.

    Time frame: From pacemaker implantation through 24 months after implantation (cumulative event count).

  13. Immediate Implantation Success

    Successful implantation of the allocated pacing strategy, reported as the number and percentage of participants meeting the arm-specific technical success criteria. For CSP, assessment includes electrophysiological evidence of conduction-system capture, sensing, capture threshold, and impedance; RVP criteria are specified separately. Numerical thresholds and mandatory tests will be prospectively approved in the electrophysiology operational appendix before first enrollment.

    Time frame: During the index implantation procedure

  14. Pacing-System Function

    Device or lead failures identified during clinical follow-up, device interrogation, or remote monitoring, including failure to capture or sense. Failures and subsequent management will be documented and relevant events reviewed by the Clinical Events Adjudication Committee.

    Time frame: From implantation through 24 months

  15. Implantation Procedure Duration

    Duration of the index pacemaker implantation procedure, measured in minutes, compared between pacing strategies.

    Time frame: During the index pacemaker implantation procedure.

  16. Length of Hospital Stay

    Duration of the hospital stay associated with the index pacemaker implantation, measured in days.

    Time frame: Periprocedural (assessed at discharge from the hospitalization for pacemaker implantation).

  17. Healthcare Resource Use

    Healthcare resources used for implantation and follow-up, including staff time, equipment, diagnostic tests, and clinical visits. Resource categories will be recorded separately rather than combined into an unvalidated score. Detailed resource definitions and analysis procedures will be finalized in the operational procedures and statistical analysis plan.

    Time frame: Day 1 (pacemaker implantation) through 24 months after implantation.

Other outcomes

  1. Left Ventricular Ejection Fraction at 12 Months

    Left ventricular ejection fraction (LVEF), expressed as a percentage and measured by echocardiography at 12 months after implantation. The 12-month comparison is exploratory; the prespecified primary comparison is at 24 months.

    Time frame: 12 months after implantation

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.

Of 44 interventional studies with no phase under Atrioventricular Block, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 36 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 18, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2032
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945860
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2032 (estimated)
Last update
Nov 18, 2026

Study contacts

Yair Edden, MD
Contact
Yair.Edden@sheba.health.gov.il
+972-52-6667410
Yair Edden, MD
principal investigator · Sheba Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion